Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel®

Vivos Inc. (OTCQB: RDGL) has appointed the esteemed Dr. John J. Smith, M.D., J.D., as its lead regulatory advisor to aid in the submission of the Investigational Device Exemption (IDE) for their innovative product, RadioGel®. Based in Washington, D.C., Dr. Smith is a partner at Hogan Lovells and is recognized nationally for his expertise in FDA regulations regarding medical devices. His experience as a board-certified diagnostic radiologist and a former associate professor at Harvard Medical School further solidifies his qualifications.

Dr. Michael Korenko, CEO of Vivos Inc., expressed enthusiasm over Dr. Smith's re-engagement, emphasizing his unique understanding of RadioGel® and direct experience with the FDA’s Division of Radiological Imaging and Radiation Therapy Devices. This collaboration aims to address remaining deficiencies in the IDE submission, which is crucial for advancing their innovative device toward clinical trials at the esteemed Mayo Clinic.

RadioGel® is designed as a groundbreaking injectable device capable of delivering high-dose, targeted radiation directly to tumors, thus presenting a promising avenue for cancer treatment. However, the product is not yet authorized for pre-market use, making the IDE approval a pivotal step in its development.

Vivos Inc.'s decision to bring in Dr. Smith is a strategic move that aims to enhance the clarity and confidence surrounding their regulatory journey. The company is navigating the complexities of the FDA approval process, and having a top regulatory consultant like Dr. Smith offers a significant advantage. The press release also highlights the risks involved in their operations and the forward-looking nature of their statements, urging stakeholders to consult their SEC filings for more comprehensive insights.

Vivos Inc. (OTCQB: RDGL) has made a strategic move by appointing Dr. John J. Smith, a key regulatory expert, to guide their FDA Investigational Device Exemption (IDE) submission for RadioGel®. This appointment signals a strong commitment to navigating the complex regulatory landscape necessary for bringing innovative medical devices to market. Investors should view this as a positive development given Dr. Smith's substantial experience and past relationship with Vivos, which suggests a streamlined approach to addressing any outstanding issues with the FDA.

RadioGel® itself is positioned as a cutting-edge injectable device aimed at delivering targeted radiation therapy to tumors. Its success hinges on obtaining FDA approval, which would facilitate clinical trials at the renowned Mayo Clinic. Gaining IDE approval is crucial for Vivos as it not only serves as a validation of the product's safety and efficacy but also positions the company favorably within the competitive landscape of medical oncology innovations.

From a market perspective, the appointment of seasoned regulatory advisors is a strategic maneuver that may bolster investor confidence. Given the complexities associated with FDA regulations, having a team that understands the nuances of the Division of Radiological Imaging and Radiation Therapy Devices could prove invaluable in expediting approval processes.

Nevertheless, potential investors should remain cautious. The company's path to clinical trials is fraught with regulatory risks, and operational challenges are not uncommon in the medical device sector. The forward-looking statements included in the press release highlight this uncertainty, thus reinforcing the need for due diligence.

Investors should monitor Vivos Inc. closely, especially as milestones related to the IDE submission approach. The combination of innovative technology and expert regulatory guidance could position Vivos favorably should they secure the necessary approvals, making this a potentially lucrative opportunity for forward-thinking investors.